Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg

Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg Elmwood Park , New Jersey, March 19, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. Glenmark’s Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella®2 Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. According to IQVIATM sales data for the 12-month period ending January 2026, the Savella® Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market2 achieved annual sales of approximately $102.9 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg, the authorized generic to Savella® Tablets. This launch further strengthens our commitment to bring to market quality and affordable alternatives for patients.” 1Glenmark’s Milnacipran Hydrochloride Tablets is only approved for the indication(s) listed in Glenmark’s approved label. 2All brand names and trademarks are the property of their respective owners. 3Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications. *IQVIATM National Sales Perspectives: Retail & Non-Retail, January 2026 About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research ‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting - edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diver sified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com. For more information, please contact: In the U.S.: Akhila Natarajan [email protected] +91 98216 89525 Danielle Hagen, Nahigian Strategies [email protected] 202-365-6112 In India: Akhila Natarajan [email protected] +91 98216 89525 Adfactors PR [email protected] +91 88502 91322

The release as fetched from its publisher. glenmarkpharma.com ↗